<![CDATA[Lirafugratinib Displays Antitumor Activity in Advanced FGFR2-Mutated CCA]]>
Treatment with 70 mg of daily lirafugratinib displayed positive antitumor activity among patients previously treated for unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring FGFR2 fusions or rearrangements, according to an …